Company news
Quantum Biopharma Ltd. Subordinate Voting Shares news in 2024
Quantum Biopharma Ltd. Subordinate Voting Shares's news releases, calls and decks from 2024, newest first.
Quantum Biopharma Announces Closing of Second Tranche
December 20, 2024
Quantum Biopharma Diversifies Treasury With the Purchase of USD $1,000,000 of Bitcoin (BTC) and Other Cryptocurrencies and to Allow for Future Financings and Other Transactions in Cryptocurrency
December 20, 2024
Quantum Biopharma Announces Closing of First Tranche
December 13, 2024
Quantum Biopharma Announces That the Safety Review Committee Recommends Commencing Dosing of Second Cohort in the Phase 1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-MS)
December 10, 2024
Quantum Biopharma Announces Non-Brokered Private Placement of Convertible Debenture Units for Gross Proceeds of Up to $5 Million
December 5, 2024
Quantum BioPharma Previously Known as FSD Pharma (Nasdaq: HUGE) (CSE: HUGE) Invites Shareholders to Come Forward and Join Hands With the Company in the US700M$+ Court Case the Company Has Filed Against CIBC, RBC, and Others for Alleged Spoofing/Stock Price Manipulation
November 25, 2024
Quantum Biopharma Announces that Sentinel Dosing has Started for the Phase-1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-Ms) in Australia
October 29, 2024
Quantum Biopharma (NASDAQ: QNTM) Posts Link on Its Website to Access the Filed Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing
October 22, 2024
Quantum BioPharma Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing
October 21, 2024
Quantum BioPharma (Nasdaq: QNTM) Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing
October 21, 2024
Quantum BioPharma Ltd. Alleges Market Manipulation, Files Lawsuit, unbuzzed Continues To Gain Traction
October 20, 2024
Quantum BioPharma Ltd. (NASDAQ: QNTM): Pioneering Alcohol Metabolism Support with Unbuzzd
October 14, 2024
Quantum BioPharma Ltd. Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group across Puerto Rico, The Caribbean, and Parts of Central and South America
October 7, 2024
Quantum BioPharma Ltd. Pharma Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group Across Puerto Rico, the Caribbean, and Parts of Central and South America
October 7, 2024
Quantum Biopharma Provides Corporate Update
September 27, 2024
Quantum BioPharma to Present at Global Growth and Investment Conference Presented by ArcStone Securities and Invesments and Kingswood US
September 25, 2024
Quantum BioPharma Closes Private Placement Offering
September 12, 2024
Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis
September 9, 2024
Quantum Biopharma Receives Nasdaq Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement and Completes Debt Settlements
September 6, 2024
Quantum Biopharma Announces Celly Nutrition Launches unbuzzd(TM) Grab-and-Go Stick Packs on Amazon.com so you can "own NOW and what's NEXT"
August 30, 2024
FSD Pharma Completes Name Change to Quantum BioPharma and 65: 1 Consolidation - Trading Under New Ticker Symbol "QNTM"
August 15, 2024
FSD Pharma Announces Share Consolidation and Name Change
August 8, 2024
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp. Who Secures Additional Financing to Launch unbuzzd(TM) Stick Packs this Month - Created by a World-Class Pharmaceutical Research & Development Team
August 9, 2024
24/7 Market News Publishes Report Covering Functional Beverage Market, Featuring FSD Pharma
July 25, 2024
FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders
July 23, 2024
24/7 Market News Publishes Report Covering Biotech Developments, Featuring FSD Pharma
July 23, 2024
FSD Pharma Files Amended and Restated Material Change Report
July 4, 2024
FSD Pharma provides Corporate Update
June 28, 2024
FSD Pharma, Inc. Wins Final Judgment to Confirm Arbitration Award of $3,059,998 Plus Interest Entered Against Dr. Raza Bokhari, Currently Serving as Chairman and CEO of Medicus Pharma Ltd.
June 28, 2024
FSD Pharma Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in Australia
June 27, 2024
FSD Pharma Enters Into an Exclusive Option Agreement With the University of Southern California To Evaluate Novel Dietary Supplement Technology for unbuzzd(TM) and Other Business Applications
June 13, 2024
FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication
June 4, 2024
FSD Pharma, Inc. Wins Petition to Confirm Arbitration Awards Entered Against Dr. Raza Bokhari Totaling Over $3 Million CAD, Plus Interest
May 31, 2024
FSD Pharma Submits a Clinical Trial Protocol to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication
May 28, 2024
FSD Pharma Provides Corporate Update
May 24, 2024
FSD Pharma Provides Update on Celly Nu's New Packaging for unbuzzd(TM)
May 16, 2024
FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia
May 7, 2024
FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication
April 30, 2024
FSD Pharma Provides Update from Celly Nu's Partnership with Six+One for unbuzzd(TM)
April 25, 2024
FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd(TM)
April 22, 2024
FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products
April 17, 2024
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption
April 7, 2024
FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
April 7, 2024
FSD Pharma Announces Filing of Year-End 2023 Results
April 1, 2024
FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults
March 27, 2024
FSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd(TM)
March 11, 2024
FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum
March 5, 2024
FSD Pharma Announces Debt Settlement
February 28, 2024
FSD Pharma Signs Agreement With Ingenu CRO to Conduct a Clinical Trial To Determine the Safety and Efficacy Effects of its Proprietary Blend Beverage unbuzzd(TM)
February 26, 2024
FSD Pharma Announces US ATM Offering
February 16, 2024